Unfortunately, the study only described the pathophysiological potential of parasympathetic denervation in PD patients, owing to the constraint of technical problems, rather than demonstrating that AChE activity testing gives an acceptable clinical diagnostic for PD diagnosis (Fedorova et al., 2015) (see Table 3)
Preclinical studies have suggested potential biomarkers such as circulating free IGF levels, mutations of p53, BRCA1, KRAS and BRAF, IRS2 copy number gain, InsR/IGF-IR overexpression, InsR/IGF-IR pathway activation, PTEN loss, CD24, mesenchymal markers, -catenin/TCF activity, FUS-DDIT3 fusion, and ERG [192,193,194,195,196,197,198,199,200,201]
Cell 2016
in the 100 mg dose present here, serious GI effects are uncommon, but mild nausea or stomach discomfort could occur in sensitive patients